Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedImmune’s CytoGam

Executive Summary

Beginning Phase I/II trials for CMV in AIDS patients. The study of the cytomegalovirus immune globulin product is expected to be completed by September with Phase III efficacy trials projected to begin in autumn. CytoGam is already approved for the prevention of primary CMV in kidney transplant patients and Gaithersburg, Md.-based MedImmune will be seeking expanded labeling through submission of data on the use of the product to prevent CMV in liver transplant patients.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS020664

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel